The biochemical mechanism controlling nucleation of mineral crystals in developing bone, along with the growth and propagation of these crystals once formed, remains poorly understood. To define the nucleation mechanism, a proteomics analysis was begun on isolated biomineralization foci (BMF), sites of initial crystal nucleation in osteoblastic cell cultures and in primary bone. Comparative analyses of the protein profile for mineralized BMF with that for total osteoblast cultures revealed the latter were enriched in several proteins including BAG-75 and BSP, as well as fragments of each. When 12 protease inhibitors were added separately to UMR 106-01 osteoblastic cultures, only the serine protease inhibitor 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF) blocked cleavage of BAG-75 and BSP, and prevented mineral crystal nucleation within BMF. Consideration of the specificities of the inhibitors tested and the fact that AEBSF inhibition was not dependent upon inclusion of FBS in the culture media indicated that mineral nucleation does not require serine protease plasmin, thrombin, kallikrein, urokinase, C1s or furin. In contrast, SKI-1 (S1P or site-1) is a membrane-bound serine protease inhibitable by AEBSF. We show here for the first time that mineralizing UMR 106 cells express a 98-kDa active, soluble form of SKI-1 within BMF. In contrast, nonmineralizing UMR cells appear to differentially process SKI-1 into smaller immunoreactive fragments (<35 kDa). These findings suggest that SKI-1 plays a direct or indirect role in assembly of functional nucleation complexes containing BAG-75 and BSP and their fragments, thus facilitating initial mineral nucleation within these biomineralization foci.

Keywords:
Biomineralization, Bone cell biology, Intramembranous bone, Calcification mechanisms, Extracellular matrix, Laser microscopy, Proteins, SKI-1, Protease
1.
Basak, S., N.A. Stewart, M. Chretien, A. Basak (2004) Aminoethyl benzenesulfonyl fluoride and its hexapeptide (Ac-VFRSLK) conjugate are both in vitro inhibitors of subtilisin kexin isozyme-1. FEBS Lett 573: 186–194.
2.
Benjannet, S., D. Rhainds, R. Essalmani, J. Mayne, L. Wickham, W. Jin, M.C. Asselin, J. Hamelin, M. Varret, D. Allard, M. Trillard, M. Abifadel, A. Tebon, A.D. Attie, D.J. Rader, C. Boileau, L. Brissette, M. Chretien, A. Prat, N.G. Seidah (2004) NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 279: 48865–48875.
3.
Chen, Y., B.S. Bal, J.P. Gorski (1992) Calcium and collagen binding properties of osteopontin, bone sialoprotein, and bone acidic glycoprotein-75 from bone. J Biol Chem 267: 24871–24878.
4.
Elagoz, A., S. Benjannet, A. Mammarbassi, L. Wickham, N.G. Seidah (2002) Biosynthesis and cellular trafficking of the convertase SKI-1/S1P: ectodomain shedding requires SKI-1 activity. J Biol Chem 277: 11265–11275.
5.
Goldberg, H.A., K.J. Warner, M.J. Stillman, G.K. Hunter (1996) Determination of the hydroxyapatite-nucleating region of bone sialoprotein. Connect Tissue Res 35: 385–392.
6.
Gorski, J.P. (1998) Is all bone the same? Distinctive distributions and properties of non-collagenous matrix proteins in lamellar vs. woven bone imply the existence of different underlying osteogenic mechanisms. Crit Rev Oral Biol Med 9: 201–223.
7.
Gorski, J.P., D. Griffin, G. Dudley, C. Stanford, R. Thomas, C. Huang, E. Lai, B. Karr, M. Solursh (1990) Bone acidic glycoprotein-75 is a major synthetic product of osteoblastic cells and localized as 75- and/or 50-kDa forms in mineralized phases of bone and growth plate and in serum. J Biol Chem 265: 14956–14963.
8.
Gorski, J.P., A. Wang, D. Lovitch, D. Law, K. Powell, R.J. Midura (2004) Extracellular bone acidic glycoprotein-75 defines condensed mesenchyme regions to be mineralized and localizes with bone sialoprotein during intramembranous bone formation. J Biol Chem 279: 25455–25463.
9.
Huffman, N.T., J.A. Keightley, C. Chaoying, R.J. Midura, D. Lovitch, P.A. Veno, S.L. Dallas, J.P. Gorski (2007) Association of specific proteolytic processing of bone sialoprotein and bone acidic glycoprotein-75 with mineralization within biomineralization foci. J Biol Chem 282: 26002–26013.
10.
Kimmel, D.B., W.S. Jee (1980) A quantitative histologic analysis of the growing long bone metaphysis. Calcif Tissue Int 32: 113–122.
11.
Leighton, M., K.E. Kadler (2003) Paired basic/Furin-like proprotein convertase cleavage of Pro-BMP-1 in the trans-Golgi network. J Biol Chem 278: 18478–18484.
12.
Mark, H., A. Nilsson, U. Nannmark, B. Rydevik (2004) Effects of fracture fixation stability on ossification in healing fractures. Clin Orthop Relat Res 419: 245–250.
13.
Midura, R.J., A. Wang, D. Lovitch, D. Law, K. Powell, J.P. Gorski (2004) Bone acidic glycoprotein-75 delineates the extracellular sites of future bone sialoprotein accumulation and apatite nucleation in osteoblastic cultures. J Biol Chem 279: 25464–25473.
14.
Okada, T., K. Haze, S. Nadanaka, H. Yoshida, N.G. Seidah, Y. Hirano, R. Sato, M. Negishi, K. Mori (2003) A serine protease inhibitor prevents endoplasmic reticulum stress- induced cleavage but not transport of the membrane-bound transcription factor ATF6. J Biol Chem 278: 31024–31032.
15.
Pasquato, A., P. Pullikotil, M.C. Asselin, M. Vacatello, L. Paolillo, F. Ghezzo, F. Basso, C. Di Bello, M. Dettin, N.G. Seidah (2006) The proprotein convertase SKI-1/S1P. In vitro analysis of Lassa virus glycoprotein-derived substrates and ex vivo validation of irreversible peptide inhibitors. J Biol Chem 281: 23471–23481.
16.
Pullikotil, P., S. Benjannet, J. Mayne N.G. Seidah (2007) The proprotein convertase SKI-1/S1P: alternate translation and subcellular localization. J Biol Chem 282: 27402–27413.
17.
Seidah, N.G., M. Chretien (1999) Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res 848: 45–62.
18.
Seidah, N.G., A.M. Khatib, A. Prat (2006) The proprotein convertases and their implication in sterol and/or lipid metabolism. Biol Chem 387: 871–877.
19.
Seidah, N.G., S.J. Mowla, J. Hamelin, A.M. Mamarbachi, S. Benjannet, B.B. Toure, A. Basak, J.S. Munzer, J. Marcinkiewicz, M. Zhong, J.C. Barale, C. Lazure, R.A. Murphy, M. Chretien, M. Marcinkiewicz (1999) Mammalian subtilisin/kexin isozyme SKI-1:A widely expressed proprotein convertase with a unique cleavage specificity and cellular localization. Proc Natl Acad Sci USA 96: 1321–1326.
20.
Seidah, N.G., A. Prat (2002) Precursor convertases in the secretory pathway, cytosol and extracellular milieu. Essays Biochem 38: 79–94.
21.
Steiglitz, B.M., M. Ayala, K. Narayanan, A. George, D.S. Greenspan (2004) Bone morphogenetic protein-1/Tolloid-like proteinases process dentin matrix protein-1. J Biol Chem 279: 980–986.
22.
Turner, C.H., M.R. Forwood, J.Y. Rho, T. Yoshikawa (1994) Mechanical loading thresholds for lamellar and woven bone formation. J Bone Miner Res 9: 87–97.
23.
Wang, A., J.A. Martin, L.A. Lembke, R.J. Midura (2000) Reversible suppression of in vitro biomineralization by activation of protein kinase A. J Biol Chem 275: 11082–11091.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.